Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Renal Insufficiency 3Kidney Failure, Chronic 3Multiple Myeloma 2Carcinoma, Renal Cell 2Virus Diseases 1Renal Insufficiency, Chronic 1Kidney Diseases 1Hematologic Neoplasms 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1

Interventions

Nivolumab 143pembrolizumab 129Sunitinib 127Bevacizumab 71Everolimus 70Sorafenib 68cabozantinib 64Ipilimumab 61pazopanib 58Axitinib 57aldesleukin 51Magnetic Resonance Spectroscopy 43Cyclophosphamide 40Interleukin-2 38lenvatinib 36Radiosurgery 36Specimen Handling 33Interferon-alpha 32atezolizumab 29belzutifan 24temsirolimus 23Gemcitabine 23fludarabine phosphate 22Radiotherapy 18Interferon alpha-2 18Biopsy 18fludarabine 17durvalumab 17avelumab 17Paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Renal Cell × Kidney Transplantation × Clear all
NCT05725421 2026-05-28

Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy

Case Comprehensive Cancer Center

Phase NA Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT07053462 2025-07-08

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Failure, Chronic, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡